Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

5,059 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Effects of drug discontinuation after short-term daily alendronate administration on osteoblasts and osteocytes in mice.
Tsuboi K, Hasegawa T, Yamamoto T, Sasaki M, Hongo H, de Freitas PH, Shimizu T, Takahata M, Oda K, Michigami T, Li M, Kitagawa Y, Amizuka N. Tsuboi K, et al. Among authors: Sasaki M. Histochem Cell Biol. 2016 Sep;146(3):337-50. doi: 10.1007/s00418-016-1450-7. Epub 2016 May 27. Histochem Cell Biol. 2016. PMID: 27235014
A paradigm shift for bone quality in dentistry: A literature review.
Kuroshima S, Kaku M, Ishimoto T, Sasaki M, Nakano T, Sawase T. Kuroshima S, et al. Among authors: Sasaki M. J Prosthodont Res. 2017 Oct;61(4):353-362. doi: 10.1016/j.jpor.2017.05.006. Epub 2017 Jun 17. J Prosthodont Res. 2017. PMID: 28633987 Review.
Effect of anti-angiogenesis induced by chemotherapeutic monotherapy, chemotherapeutic/bisphosphonate combination therapy and anti-VEGFA mAb therapy on tooth extraction socket healing in mice.
Akita Y, Kuroshima S, Nakajima K, Hayano H, Kanai R, Sasaki M, Sawase T. Akita Y, et al. Among authors: Sasaki M. J Bone Miner Metab. 2018 Sep;36(5):547-559. doi: 10.1007/s00774-017-0872-1. Epub 2017 Oct 17. J Bone Miner Metab. 2018. PMID: 29043461
Prevalence of bisphosphonate-related osteonecrosis of the jaw-like lesions is increased in a chemotherapeutic dose-dependent manner in mice.
Kuroshima S, Sasaki M, Nakajima K, Tamaki S, Hayano H, Sawase T. Kuroshima S, et al. Among authors: Sasaki M. Bone. 2018 Jul;112:177-186. doi: 10.1016/j.bone.2018.05.001. Epub 2018 May 2. Bone. 2018. PMID: 29729428
Low-dose CY (50 mg/kg; CY-L), moderate-dose CY (100 mg/kg; CY-M), high-dose CY (150 mg/kg; CY-H), and bisphosphonate [Zometa (ZA): 0.05 mg/kg] were administered for 7 weeks. ...Interestingly, anti-angiogenesis was noted regardless of CY dose and ZA administration, even though only CY-M/ZA and CY-H/ZA combination therapies induced BRONJ-like lesions. ...
Low-dose CY (50 mg/kg; CY-L), moderate-dose CY (100 mg/kg; CY-M), high-dose CY (150 mg/kg; CY-H), and bisphosphonate [Zometa (ZA): 0. …
Medication-related osteonecrosis of the jaw: A literature review.
Kuroshima S, Sasaki M, Sawase T. Kuroshima S, et al. Among authors: Sasaki M. J Oral Biosci. 2019 Jun;61(2):99-104. doi: 10.1016/j.job.2019.03.005. Epub 2019 May 15. J Oral Biosci. 2019. PMID: 31109863 Review.
5,059 results
Jump to page
Feedback